GlobeNewsWire
31 Mar 2026, 20:05 UTC · 25w ago
Verdict
Headline takes no side. We score 2096 +0.40 across three claims — moderately bullish.
+0.40moderately bullish
More positive than 66% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
NextCure will present an abstract for its investigational antibody drug conjugate SIM0505 at the ASCO 2026 meeting.
More positive than 79% of claims this week
SIM0505 is currently in an open-label Phase 1 study targeting advanced solid tumors, specifically platinum-resistant ovarian cancer.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 53% of claims this week
NextCure holds exclusive global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan.
More positive than 44% of claims this week
Which stocks this story touches
More positive than 66% of ticker scores this week
Its subsidiary's drug candidate SIM0505 had an abstract accepted for presentation at the ASCO 2026 meeting.
More positive than 66% of ticker scores this week
The company's drug candidate SIM0505 had an abstract accepted for presentation at the ASCO 2026 meeting.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
No price for 2096 right now — the quote feed didn't answer.
2096 chart →
